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Abstract: AIMS The 5-item PRECISE-DAPT, integrating age, haemoglobin, white-blood-cell count,
creatinine clearance, and prior bleeding, predicts bleeding risk in patients on dual antiplatelet therapy
(DAPT) after stent implantation. We sought to assess whether the bleeding risk prediction offered by
the PRECISE-DAPT remains valid among patients receiving ticagrelor monotherapy from 1 month on-
wards after coronary stenting instead of standard DAPT and having or not having centrally-adjudicated
bleeding endpoints. METHODS AND RESULTS The PRECISE-DAPT was calculated in 14,928 and
7,134 patients from GLOBAL LEADERS and GLASSY trials, respectively. The ability of the score
to predict BARC 3 or 5 bleeding was assessed and compared among patients on ticagrelor monother-
apy (experimental strategy) or standard DAPT (reference strategy) from 1 month after drug-eluting
stent implantation. Bleeding endpoints were investigator-reported or centrally-adjudicated in GLOBAL
LEADERS and GLASSY, respectively.At 2 years, the c-indexes for the score among patients treated
with the experimental or reference strategy were 0.67 (95% confidence interval [CI]:0.63-0.71) vs. 0.63
(95% CI:0.59-0.67) in GLOBAL LEADERS (p = 0.27), and 0.67 (95% CI:0.61-0.73) vs. 0.66 (95%
CI:0.61-0.72) in GLASSY (p = 0.88). Decision curve analysis showed net benefit using the PRECISE-
DAPT to guide bleeding risk assessment under both treatment strategies. Results were consistent be-
tween investigator-reported and adjudicated endpoints and using the simplified 4-item PRECISE-DAPT.
CONCLUSIONS The PRECISE-DAPT offers a prediction model that proved similarly effective to pre-
dict clinically-relevant bleeding among patients on ticagrelor monotherapy from 1 month after coronary
stenting compared with standard DAPT and appears to be unaffected by the presence or absence of
adjudicated bleeding endpoints.
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Aims. The 5-item PRECISE-DAPT, integrating age, haemoglobin, white-blood-cell count, 
creatinine clearance, and prior bleeding, predicts bleeding risk in patients on dual antiplatelet 
therapy (DAPT) after stent implantation. We sought to assess whether the bleeding risk prediction 
offered by the PRECISE-DAPT remains valid among patients receiving ticagrelor monotherapy 
from 1 month onwards after coronary stenting instead of standard DAPT and having or not having 
centrally-adjudicated bleeding endpoints. 
Methods and results. The PRECISE-DAPT was calculated in 14,928 and 7,134 patients from 
GLOBAL LEADERS and GLASSY trials, respectively. The ability of the score to predict BARC 3 
or 5 bleeding was assessed and compared among patients on ticagrelor monotherapy (experimental 
strategy) or standard DAPT (reference strategy) from 1 month after drug-eluting stent implantation. 
Bleeding endpoints were investigator-reported or centrally-adjudicated in GLOBAL LEADERS and 
GLASSY, respectively. 
At 2 years, the c-indexes for the score among patients treated with the experimental or reference 
strategy were 0.67 (95% confidence interval [CI]:0.63-0.71) vs. 0.63 (95% CI:0.59-0.67) in 
GLOBAL LEADERS (p=0.27), and 0.67 (95% CI:0.61-0.73) vs. 0.66 (95% CI:0.61-0.72) in 
GLASSY (p=0.88). Decision curve analysis showed net benefit using the PRECISE-DAPT to guide 
bleeding risk assessment under both treatment strategies. Results were consistent between 
investigator-reported and adjudicated endpoints and using the simplified 4-item PRECISE-DAPT. 
Conclusions. The PRECISE-DAPT offers a prediction model that proved similarly effective to 
predict clinically-relevant bleeding among patients on ticagrelor monotherapy from 1 month after 
coronary stenting compared with standard DAPT and appears to be unaffected by the presence or 
absence of adjudicated bleeding endpoints.  
 





































































































Dual antiplatelet therapy (DAPT) reduces the risk of stent-related and spontaneous ischaemic events 
in patients undergoing percutaneous coronary intervention (PCI).1–4 This benefit comes with an 
increased risk of bleeding, which can offset the ischemic benefit and adversely impact prognosis.3,4 
Therefore, the assessment of bleeding risk after PCI is crucial to guide clinicians’ decisions with 
respect to antiplatelet therapies.1,5 The PRECISE-DAPT is a 5-item score that has been developed 
to predict bleeding risk during DAPT6 and was endorsed by a Class IIB recommendation to identify 
high bleeding risk patients (i.e., score ≥25), in whom the benefits of shorter DAPT (i.e., 3-6 
months) can outweigh the risks of extended treatment duration.1,7 Since its generation, the 
performance of the score has been tested in contemporary PCI cohorts treated with standard DAPT 
consisting of aspirin plus a P2Y12 inhibitor (i.e., 6 to 12 months) followed by aspirin 
monotherapy.8–10 Recently, several trials have challenged current DAPT paradigm and provided 
evidence that early discontinuation of aspirin followed by the continuation of potent P2Y12 
inhibitors is able to reduce overall bleeding risks without an apparent trade-off in efficacy.11–14 
Whether PRECISE-DAPT score retains consistent bleeding risk prediction capability in patients 
receiving potent P2Y12 inhibitor monotherapy is unclear. Moreover, no study so far has assessed 
whether the PRECISE-DAPT performance might be affected by the presence or absence of 
centrally-adjudicated bleeding endpoints, which carries relevant implications for practice.  
The GLOBAL LEADERS trial11 and its Adjudication Sub-Study (GLASSY)15 randomized patients 
to receive 1-month DAPT followed by 23-month ticagrelor monotherapy or 12-month DAPT 
followed by aspirin alone after new-generation drug-eluting stenting. 
We sought to assess the performance of PRECISE-DAPT score to predict bleeding risk in patients 
receiving either ticagrelor 90 mg twice daily monotherapy from 1 month after PCI or standard 
DAPT in the setting of GLOBAL LEADERS, based on investigator-reported endpoints, and 





































































































Study design and participants 
GLOBAL LEADERS (NCT01813435) is a multicenter randomized trial investigating two 
antiplatelet strategies in all-comer patients receiving drug-eluting stent for acute coronary 
syndromes (ACS) or stable coronary artery disease (CAD).11 After coronary angiography, 15,991 
patients were randomized (1:1) using a web-based-system stratified by center and clinical 
presentation. The experimental strategy consisted of 1-month DAPT (aspirin 75-100 mg plus 
ticagrelor 90 mg bid) followed by 23-month ticagrelor 90 mg bid monotherapy. The reference 
strategy consisted of standard 12-month DAPT (aspirin 75-100 mg plus clopidogrel 75 mg if stable 
CAD or ticagrelor 90 mg bid if ACS) followed by aspirin alone for 12 months.  
GLASSY (NCT03231059) is a sub-study of the GLOBAL LEADERS including adjudicated events 
from all 7,585 patients enrolled at the 20 highest recruiting sites, whereby investigator-reported 
events and triggered potential unreported events were centrally adjudicated by an independent 
Clinical Events Committee (CEC) blinded to treatment groups.15 
All participants provided written informed consent. The protocols were approved by ethic 
committees of participating institutions.  
 
PRECISE-DAPT score calculation 
The PRECISE-DAPT is a 5-item bleeding risk score, which has been generated for the prediction of 
Thrombosis in Myocardial Infarction (TIMI) out-of-hospital bleeding in patients on DAPT using 
age, creatinine clearance, white-blood-cell count, haemoglobin, and history of bleeding at baseline.6 
The PRECISE-DAPT has the potential to inform clinicians’ decision with respect to the optimal 
DAPT duration post PCI, selecting high bleeding risk patients (score ≥25) for a shorter treatment 
(i.e., 3-6 months) and non-high-risk patients for prolonged treatment (i.e., ≥12 months). A 
simplified 4-item version of the score, lacking white-blood-cells count, has also been developed and 



































































































participant as in the development cohort. The simplified 4-item version of the score was also 
computed.6 All data for score calculations were prospectively collected. 
 
Study endpoints 
The primary endpoint was bleeding type 3 or 5 defined according to the Bleeding Academic 
Research Consortium (BARC) scale,17 which was investigator-reported in GLOBAL LEADERS 
and CEC-adjudicated in GLASSY. The primary endpoint was analyzed in the overall populations 
and separately in the experimental and control groups, and across 2 years or with landmark at 1 
year. 
 
Statistical analysis  
The PRECISE-DAPT score was calculated using data collected at index PCI. Patients were 
stratified into 4 groups according to study treatment and PRECISE-DAPT (≥25 vs. <25). 
Continuous variables are expressed as mean (standard deviation) or median (interquartile range), 
and categorical variables as numbers and percentages. Differences were calculated using t-test and 
Wilcoxon-test for continuous data and χ2 or Fisher’s tests for categorical data. Kaplan-Meier 
method was used to estimate cumulative event rates and log-rank test to examine differences across 
score strata. The association between the primary endpoint and risk categories was calculated as 
hazard ratios (HR), considering very-low risk patients as reference. Discrimination was assessed 
using Harrell’s c-statistic, and compared through treatment strategies using a nonparametric test. 
Calibration was assessed by Grønnesby-Borgan χ2 test and plotted as observed versus predicted 
outcomes using Arjas plots. Continuous relation between the risk (as hazard ratio) and incidence of 
BARC 3 or 5 bleeding at follow-up and PRECISE-DAPT was assessed using restricted cubic 
splines. Net clinical benefit was determined by means of decision curve analyses.18 All analyses 








































































































Of the 15,991 and 7,585 patients enrolled in GLOBAL LEADERS and GLASSY, the PRECISE-
DAPT was available in 14,928 (93.3%) and 7,134 (94.0%), respectively. The mean score was 
16.5±8.8 in the parental trial and 16.5±8.7 in the adjudication sub-study, while the median score 
was 15.0 (interquartile range:10.0; 21.0) in both studies (Tables 1 and 2). A total of 2,483 (16.6%) 
patients in GLOBAL LEADERS and 1,180 (16.5%) in GLASSY had a PRECISE-DAPT score ≥25. 
Score distribution was similar in the experimental and control groups (Figure 1). 
In both studies, baseline characteristics were well balanced between the experimental and control 
group within PRECISE-DAPT strata (Tables 1 and 2 and supplementary material). Patients with 
high versus non-high PRECISE-DAPT differed for the 5 score covariates and were more frequently 
female, had lower body-mass index and higher rates of cardiovascular risk factors, prior myocardial 
infarction, coronary revascularization, and stroke; they also received less frequent radial access, 
single lesion intervention, or direct stenting.  
 
Bleeding risk stratification by PRECISE-DAPT score 
The risk of bleeding as estimated by Kaplan-Meier event curves differed significantly according to 
PRECISE-DAPT score with similar stratification effect for the experimental and reference strategy 
(Figure 2). At 2 years, GLOBAL LEADERS patients with PRECISE-DAPT ≥25 had significantly 
increased risk of BARC 3 or 5 bleeding in both the experimental group (HR:4.37; 95% CI:2.64-
7.23; p<0.001) and control group (HR:3.81; 95% CI:2.30-6.30; p<0.001) compared with the 



































































































the experimental group (95% CI:2.44-9.07; p<0.001) and of 3.39 in the control group (95% 
CI:1.78-6.57; p<0.001). Results were consistent in the overall study populations (Figure S1).  
The PRECISE-DAPT showed a continuous association with the risk (in terms of hazard ratio) as 
well as the incidence of BARC 3 or 5 bleeding at 1 year and 2 years, which was consistent between 
the experimental and control groups (Figure 3, and Figures S2 and S3).  
 
PRECISE-DAPT performance for bleeding prediction 
PRECISE-DAPT was effective to predict BARC 3 or 5 bleeding in patients receiving either the 
experimental or reference strategy (Tables 3 and 4, Figures S4 and S5).  
In GLOBAL LEADERS, the score showed moderate discrimination with c-index of 0.67 (95% 
CI:0.63-0.71) in the experimental group vs. 0.63 (95% CI:0.59-0.67) in the control group at 2 years 
(p=0.27). In GLASSY, the c-index was 0.67 (95% CI:0.61-0.73) in the experimental group and 0.66 
(95% CI:0.61-0.72) in the control group (p=0.88). The score was moderately calibrated in both 
treatment strategies, although the predicted and observed probability approximated more closely in 
GLOBAL LEADERS than GLASSY.  
Results were consistent at landmark analysis. In GLOBAL LEADERS, c-index estimates during the 
first and second year of follow-up were 0.68 and 0.64 in the experimental group, and 0.62 and 0.66 
in the control group, respectively. Similarly, in GLASSY, c-index values before and after the 1-year 
landmark were 0.69 and 0.61 in the experimental arm, and 0.64 and 0.75 in the control arm (Tables 
3 and 4, Figure S5). 
Discriminative ability of the 4-item PRECISE-DAPT was similar to the score including white-
blood-cell count and consistent with respect to randomized treatment strategies, although this score 
iteration appeared less well calibrated (Tables 3 and 4, Figure S6).  
 



































































































Figure 4 compares the decision curves to classify individuals using PRECISE-DAPT and its 4-item 
version assuming that all patients will bleed (i.e., all are at high risk of bleeding) or that no patient 
will bleed (i.e., all are at low risk of bleeding). For BARC 3 or 5 bleeding, decision curves showed 
that both scores were superior to the scenario of “not using scores” for risk thresholds from 1% to 
8% in all study groups (Figure 2, Figure S4). For instance, in the experimental group of GLOBAL 
LEADERS, applying a risk threshold of 3% for BARC 3 or 5 events, the use of PRECISE-DAPT 
would result in a net benefit gain of +0.27% (+0.32% for the 4-item score) and of +1.12% (1.17% 
for the 4-item score) compared with the scenario of “assuming all as high-risk” (Table S3). In other 
words, the net benefit of using the PRECISE-DAPT score leads to 37.3 (39 for the 4-item score) 
and 9 (10.6 for the 4-item score) more true-positive cases per 100 patients without additional false-
positives (i.e., “net” true-positives) compared with “assuming all as high-risk” and “assuming all as 
low-risk”, respectively. Additional case examples are reported in Tables S4-S6. 
 
Discussion 
In the current analysis, which included more than 14,000 participants of the GLOBAL LEADERS 
trial and its GLASSY sub-study, we evaluated the performance of PRECISE-DAPT score in 
patients having or not adjudicated bleeding endpoints and treated with ticagrelor plus aspirin for 1 
month followed by 23-month ticagrelor monotherapy or standard 12-month DAPT followed by 
aspirin monotherapy after PCI. The main findings are the following: 
 The PRECISE-DAPT score was able to stratify bleeding risk to a similar extent in patients 
with or without DAPT, consisting of a 12-month combination of aspirin and ticagrelor or 
aspirin and clopidogrel followed by 12-month aspirin monotherapy or 23-month ticagrelor 
monotherapy from 1-month after coronary stenting.  
 The score provided modest but consistent discrimination and good calibration for the 
prediction of BARC-defined bleeding in both study arms, with a net benefit compared with 



































































































 The score performance remained consistent for bleeding prediction within the first year, 
where mainly ticagrelor monotherapy was compared with a DAPT regimen, as well as 
during the second year, where ticagrelor monotherapy was compared with aspirin 
monotherapy. 
 The score performance remained comparable when investigator-reported bleeding, within 
GLOBAL LEADERS, or centrally-adjudicated bleeding endpoints, within GLASSY, were 
separately appraised.  
 The 4-item PRECISE-DAPT score appeared very similar to the 5-item iteration, offering a 
credible option for bleeding risk assessment if white-blood-cell count is not available. 
Current guidelines recommend with a class IIB – pending prospective validation – the use of 
bleeding prediction models to individualize DAPT duration in patients undergoing PCI.1,6 The 
PRECISE-DAPT score was developed in a large PCI-treated population receiving standard 
antiplatelet treatment, typically consisting of DAPT for 6 to 12 months followed by aspirin alone 
after P2Y12 inhibitors discontinuation.3,6 Multiple studies have assessed the score performance 
showing a consistent ability to predict bleeding among patients receiving standard DAPT.8–10  
Yet, recent studies have challenged current DAPT paradigm by investigating the potential of early 
aspirin discontinuation after PCI. The GLOBAL LEADERS11 and its Adjudication Sub-study 
GLASSY15 pioneered this approach and provided reassuring data on the safety and efficacy of 
ticagrelor monotherapy, but failed to show its superiority over standard DAPT. In the STOPDAPT-
212 and SMART-CHOICE,13 P2Y12 monotherapy – principally clopidogrel – after 1 or 3 months of 
DAPT was associated with a lower incidence of bleeding than 12-month DAPT, without an 
apparent difference in ischemic endpoints. The TWILIGHT14 and TICO19 trials provided additional 
support by demonstrating lower bleeding risks with ticagrelor monotherapy (after 3-month DAPT) 
over conventional treatment while preserving ischemic efficacy.  
Whether the PRECISE-DAPT score retains its potential to reasonably forecast bleeding in patients 



































































































remains unclear. In addition, PRECISE-DAPT was generated and externally validated in the context 
of centrally-adjudicated bleeding endpoints, and it remained unclear if its performance might be 
affected by investigator-reported endpoints.  
We showed that PRECISE-DAPT, as well as its 4-item simplified version, retains a similar capacity 
to stratify bleeding risk in PCI patients on ticagrelor monotherapy after 1-month DAPT as among 
those on standard DAPT. Regardless of the assigned treatment, the higher the score, the higher the 
risk of clinically-relevant bleeding, which increased by a factor of more than two in patients with 
18-24 points and more than 4-fold in those with ≥25 points. In GLASSY, a PRECISE-DAPT score 
of 25 conferred a 1-year risk of adjudicated BARC 3 or 5 bleeding that approximated 4% at the 
upper limit of the 95% CI – a threshold that has been recently proposed to select high bleeding risk 
patients by the Academic Research Consortium (ARC) for High Bleeding Risk.5 The lower rate of 
BARC 3 or 5 events in GLOBAL LEADERS compared with GLASSY might be explained by the 
underreporting of clinical events due to the use of investigator-reported versus centrally-adjudicated 
endpoints, respectively. In addition, the use of PRECISE-DAPT was consistently better than “not 
using risk scores” at decision curve analysis, irrespective of the implemented antiplatelet treatment. 
Indeed, under both treatment strategies, we observed a net benefit in terms of fewer false-positive 
cases across a wide range of bleeding risk thresholds, in the absence of any potential drawbacks. Of 
note, despite the pragmatic study design, the proportion of patients with score ≥25 in GLOBAL 
LEADERS and GLASSY was approximately 16% and relatively low compared with previous 
studies.6,9 
During ticagrelor monotherapy, similarly to standard DAPT, PRECISE-DAPT was reasonably 
accurate to distinguish patients who would have bled from those who would have not 
(discrimination) and predicted the level of risk subsequently observed in reality (calibration). We 
noticed a slightly better score calibration in the parental trial, while the c-index estimates were 
slightly higher but less precise (in terms of 95% CI) in GLASSY. The evaluation of scores 



































































































events can negatively affect calibration and (to a lesser extent) c-index estimates.20 GLASSY 
included about half of patients and events included in the parent trial, and this may reasonably 
account for the less precise calibration and c-index estimates observed in this cohort, with a less 
apparent effect on the latter. 
No other risk score has been so far tested for bleeding risk prediction with ticagrelor monotherapy. 
Several risk scores have been designed to predict in-hospital or 30-day bleeding (i.e., CRUSADE, 
ACUITY). At variance from these models, PRECISE-DAPT predicts long-term bleeding risk and 
therefore appears more suited for patients on ticagrelor monotherapy after a short course of DAPT. 
The comparative performance of PRECISE-DAPT versus other bleeding risk scores remains 
unclear. 
We also observed that score performance remained consistent among patients receiving aspirin 
monotherapy (i.e., reference group during the second year). Though interesting, these data should 
be interpreted cautiously considering the low number of events in this sub-group.  
Applying the score to GLOBAL LEADERS and GLASSY gave us the opportunity to test the score 
in the context of investigator-reported or adjudicated bleeding events. Our data showed the ability 
of PRECISE-DAPT to offer consistent bleeding prediction inside and outside the context of CEC-
adjudication, which carries relevant implications for practice. 
In the present analysis, PRECISE-DAPT performance was reasonable in both GLOBAL LEADERS 
and GLASSY (c-index of 0.65 and 0.67, respectively), but somewhat lower than that reported in the 
derivation and PLATO cohorts (c-index of 0.73 and 0.70, respectively).6 The relative performance 
of the score in different studies can be explained, at least in part, by differences in bleeding 
definitions and patients’ characteristics. At variance with our analysis, which included all post-PCI 
bleeding graded by BARC scale, the score has been developed to predict out-of-hospital bleeding 
according to TIMI scale.6 Noteworthy, when the score had been tested in its derivation cohort to 
predict all post-PCI bleeding (rather than out-of-hospital events), its discriminative ability for TIMI 



































































































Moreover, when BARC 3 or 5 bleeding has been used as endpoint, the score has shown a c-index of 
0.69 and 0.65 for post-PCI and post-discharge bleeding, respectively, in contemporary PCI 
registries,6,10 in line with our findings. A recent study of 904 PCI patients showed a c-index of 0.81 
for BARC ≥3a.8 However, the retrospective design, small sample size, the exclusive inclusion of 
Asian patients, and much higher than expected BARC ≥3a bleeding (17% at 1 year) potentially 
limit data generalizability.8 Higher score performance for predicting BARC 3 or 5 bleeding (c-index 
of 0.73) has also been reported in 1,926 ACS patients.9 Yet, differences in bleeding characterization 
(out-of-hospital events assessed through medical records), population’s characteristics, and study 
design can possibly account for these discrepancies 9.  
Our study has several limitations. First, this analysis was prespecified, yet the results should be 
considered hypothesis-generating. Second, the PRECISE-DAPT was not available in approximately 
6% of patients that were excluded. Third, differences in bleeding definition used as compared with 
the derivation cohort may have affected the score performance. Finally, approximately 20% of 
GLOBAL LEADERS and GLASSY patients were non-adherent to study treatment. Prior on- versus 




The PRECISE-DAPT consistently predicts bleeding risk in patients on ticagrelor monotherapy after 
1-month DAPT or on aspirin monotherapy after 12-month DAPT as compared with patients on 
standard DAPT after drug-eluting stent implantation. Our analysis also suggests that the score 
performance is unaffected by the presence or absence of adjudicated bleeding endpoints, which 
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Table 1. Baseline characteristics of the GLOBAL LEADERS population stratified by PRECISE-
DAPT. 






















Age (years) 74.9±8.0 75.0±7.9 0.58  62.5±9.5 62.5±9.5 0.93 <0.001 
Females 499 (40.0%) 
470 
(38.1%) 




Body mass index 
(kg/m²) 
28.0±4.5 27.9±4.7 0.59  28.2±4.6 28.3±4.6 0.69 0.001 
Diabetes mellitus 465 (37.3%) 
432 
(35.0%) 













Hypertension 1,092 (87.6%) 
1,019 
(82.7%) 




Hypercholesterolemia 847 (70.3%) 
854 
(70.8%) 




Current smoker 160 (12.8%) 
154 
(12.5%) 













Previous PCI 433 (34.8%) 
461 
(37.4%) 












































Clinical presentation              


















Unstable angina 161 (12.9%) 
148 
(12.0%) 




Non-STEMI 272 (21.8%) 
301 
(24.4%) 




STEMI 196 (15.7%) 
149 
(12.1%) 




PRECISE-DAPT         













Sample sizes (n); counts (%); means (±standard deviations) or medians (25%-75% interquartile range). 



































































































Table 2. Baseline characteristics of the GLASSY population stratified by PRECISE-DAPT. 





















Age (years) 75.5± 7.7 75.9±7.6 0.48 62.8±9.4 62.7±9.5 0.62 <0.001 









Body mass index (kg/m²) 27.8±4.3 27.5±4.4 0.32 28.0±4.6 28.0±4.5 0.75 0.02 











80 (13.2%) 75 (13.1%) 1.00 
 
166 (5.6%) 175 (5.8%) 0.73 <0.001 































Previous PCI 204 (33.6%) 
234 
(40.8%) 





artery by-pass graft 
39 (6.4%) 55 (9.6%) 0.05  154 (5.2%) 170 (5.7%) 0.45 0.001 
Previous stroke 33 (5.4%) 25 (4.4%) 0.42  62 (2.1%) 66 (2.2%) 0.79 <0.001 
Peripheral vascular 
disease 
79 (13.0%) 74 (12.9%) 1.00  165 (5.6%) 207 (6.9%) 0.03 <0.001 
Previous major bleeding 25 (4.1%) 18 (3.1%) 0.43 0 (0.0%) 0 (0.0%) - <0.001 
Impaired renal function 349 (57.5%) 
315 
(55.0%) 
0.41  142 (4.8%) 152 (5.1%) 0.67 <0.001 
Chronic obstructive 
pulmonary disease 
53 (8.7%) 56 (9.8%) 0.61  136 (4.6%) 139 (4.6%) 0.95 <0.001 
Clinical presentation 











































PRECISE-DAPT         













Sample sizes (n), counts (%), means (±standard deviations) or medians (25%-75% interquartile range). 




































































































Table 3. Harrell's c-indexes and goodness-of-fit for BARC 3 or 5 bleeding in GLOBAL LEADERS. 
 






































































10.2 0.07   
0.68 
(0.62-0.73) 
9.8 0.08   
0.60  
(0.55-0.65) 
5.2 0.39 0.14 





















7.8 0.16   
0.68  
(0.64-0.72) 
11 0.05   
0.61  
(0.57-0.65) 
5.2 0.39 0.14 





















4.5 0.48   
0.69  
(0.61-0.76) 
3.2 0.67   
0.66  
(0.57-0.75) 



































































































Table 4. Harrell's c-indexes and goodness-of-fit for BARC 3 or 5 bleeding in GLASSY. 



























































6.6 0.25   
0.70  
(0.63-0.76) 
5.1 0.40   
0.63  
(0.57-0.69) 
4.7 0.45 0.30 



















9.5 0.09   
0.69  
(0.63-0.74) 
7.4 0.19   
0.65  
(0.60-0.71) 
5.6 0.34 0.51 


















7.3 0.19   
0.66  
(0.55-0.77) 
5.3 0.37   
0.74  
(0.62-0.86) 
9.3 0.09 0.30 
 





































































































Figure 1. PRECISE-DAPT score distribution in GLOBAL LEADERS and GLASSY 
according to the treatment strategy. Experimental and control groups in GLOBAL LEADERS 
(A,B) and GLASSY (C,D).  
 
Figure 2. BARC 3 or 5 bleeding at 2 years in GLOBAL LEADERS and GLASSY stratified by 
PRECISE-DAPT score. Kaplan-Meier event curves for BARC 3 or 5 bleeding at 2 years. 
Experimental and control groups in GLOBAL LEADERS (A,C) and GLASSY (B,D). BARC, 
Bleeding Academic Research Consortium Criteria; HR, Hazard ratio. 
 
Figure 3. Spline functions of BARC 3 or 5 bleeding risk at 2 years according to PRECISE-
DAPT. Experimental and control groups in GLOBAL LEADERS (A), and GLASSY (B). BARC, 
Bleeding Academic Research Consortium Criteria; CI, confidence interval; HR, hazard ratio. 
 
Figure 4. Decision curves showing net benefit of using the PRECISE-DAPT or the 4-item 
PRECISE-DAPT for predicting BARC 3 or 5 bleeding at 2 years. Experimental and control 
groups in GLOBAL LEADERS (A,B) and GLASSY (C,D). Black horizontal line: treat all 
assuming at low risk of bleeding. Green line: treat all assuming at high-risk of bleeding. Red curve: 
PRECISE-DAPT. Yellow curve: 4-item PRECISE-DAPT. Decision curves are drawn by plotting 
net benefit (y-axis) at different risk thresholds (x-axis) to visually estimate and compare the benefit 
offered by different strategies. BARC, Bleeding Academic Research Consortium Criteria. 
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